Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 5, 2026, 7:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–11 of 11 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Multifocal Motor Neuropathy
Interventions
Immune Globulin Intravenous (human), 10%, 0.25% human albumin solution (Placebo)
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
12
States / cities
Los Angeles, California • Stanford, California • Centennial, Colorado + 9 more
Conditions
Schizophrenia
Interventions
Event-Related Potentials (ERP) and Electroencephalogram (EEG) testing with the COGNISION® System
Device
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 50 Years
Enrollment
161 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
4
States / cities
Garden Grove, California • Torrance, California • Marlton, New Jersey + 1 more
Conditions
Schizophrenia
Interventions
MEM 3454, Placebo for MEM 3454
Drug
Lead sponsor
Memory Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Conditions
Multifocal Motor Neuropathy (MMN)
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
6
States / cities
Scottsdale, Arizona • Glenview, Illinois • Minneapolis, Minnesota + 3 more
Completed Phase 1 Interventional Accepts healthy volunteers

GABA-glutamate Interactions and Psychosis

NCT00611572
Conditions
Cognitive Dysfunction
Interventions
iomazenil
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2018
U.S. locations
1
States / cities
West Haven, Connecticut
Conditions
Multifocal Motor Neuropathy
Interventions
ARGX-117, Placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Scottsdate, Arizona • San Francisco, California • Washington D.C., District of Columbia + 10 more
Completed Early Phase 1 Interventional Accepts healthy volunteers

Effects of Ketamine on ERP/EEG Measures in Healthy Volunteers

NCT04928703
Conditions
Healthy
Interventions
Ketamine
Drug
Lead sponsor
ERP Biomarker Qualification Consortium
Industry
Eligibility
21 Years to 40 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Marlton, New Jersey
Conditions
Multifocal Motor Neuropathy
Interventions
Not listed
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Orange, California + 21 more
Conditions
Multifocal Motor Neuropathy (MMN), MMN
Interventions
Empasiprubart, IVIG (Intravenous Immunoglobulin), Empasiprubart-placebo, IVIg-placebo
Biological · Other
Lead sponsor
argenx
Industry
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
24
States / cities
Scottsdale, Arizona • Pomona, California • Rancho Mirage, California + 20 more
Completed Phase 1 Interventional Results available

CVN058 Effect on Mismatch Negativity in Schizophrenics

NCT03669250
Conditions
Schizophrenia
Interventions
CVN058, Placebo comparator
Drug · Other
Lead sponsor
Cerevance Alpha, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
3
States / cities
New York, New York
Conditions
Multifocal Motor Neuropathy
Interventions
Claseprubart, Placebo
Drug
Lead sponsor
Dianthus Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
9
States / cities
Scottsdale, Arizona • Los Angeles, California • Bradenton, Florida + 6 more